Value of urinary TWIST1 gene methylation detection in postoperative monitoring of bladder cancer
-
摘要: 目的 探索尿液 TWIST1 基因甲基化检测在膀胱癌术后复发监测中的预测作用。方法 应用 TWIST1 基因甲基化试剂盒对接受经尿道膀胱肿瘤切除术治疗的51例非肌层浸润性膀胱癌患者进行随访复查，对比膀胱镜检查评估其价值，并对患者临床病理资料以及术后复发情况进行统计学分析。结果 16例患者尿液 TWIST1 基因甲基化检测阳性，以同期膀胱镜检为标准，灵敏度达78.9%、特异度96.8%、阳性预测值93.7%、阴性预测值88.5%。结论 尿液 TWIST1 基因甲基化检测可作为膀胱肿瘤患者电切术后复发的有效监测手段。Abstract: Objective To explore the predictive value of urinary TWIST1 gene methylation detection in postoperative recurrence monitoring of bladder cancer.Methods Fifty-one patients with non-muscle invasive bladder cancer who underwent transurethral resection of bladder tumor were followed up with TWIST1 gene methylation detection kit. The value of cystoscopy was evaluated, and the clinicopathological data and postoperative recurrence were statistically analyzed.Results Sixteen patients were detected to have TWIST1 gene methylation in urine. The sensitivity and specificity were 78.9% and 96.8%, respectively. The positive and negative predictive values were 93.7% and 88.5%, respectively, using cystoscopy as the standard.Conclusion Detection of TWIST1 gene methylation in urine can be used as an effective method to monitor the recurrence of bladder cancer after transurethral resection of bladder cancer.
-
Key words:
- bladder cancer /
- postoperative follow-up /
- TWIST1 gene /
- methylation
-
-
表 1 51例患者临床病理特征与尿液 TWIST1 基因甲基化的关系
例 项目 总例数(51例) TWIST1阳性(16例) TWIST1阴性(35例) P值 年龄 0.370 ≥65岁 27 7 20 < 65岁 24 9 15 性别 0.770 男 38 12 26 女 13 4 9 吸烟史 0.950 有 22 7 15 无 29 9 20 血尿 0.780 有 10 3 7 无 41 13 28 分级 0.005 G1/G2 33 6 27 G3 18 10 8 分期 0.001 Ta 32 5 27 Tis/T1 19 11 8 
下载: 导出CSV
表 3 不同分组尿液 TWIST1 基因甲基化检测和膀胱镜检查的一致性比较
例 危险度 TWIST1 膀胱镜 阳性 阴性 阳性 阴性 低危组 0 16 0 16 中危组 2 8 4 6 高危/极高危组 14 11 15 10
下载: 导出CSV
-
[1] Enokida H, Nakagawa M. Epigenetics in bladder cancer[J]. Int J Clin Oncol, 2008, 13(4): 298-307. doi: 10.1007/s10147-008-0811-1
[2] Papanicolau-Sengos A, Aldape K. DNA methylation profiling: an emerging paradigm for cancer diagnosis[J]. Annu Rev Pathol, 2022, 17: 295-321. doi: 10.1146/annurev-pathol-042220-022304
[3] Wu JL, Lin YD, Yang KW, et al. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial[J]. Mol Cancer, 2024, 23(1): 57. doi: 10.1186/s12943-024-01974-4
[4] Franco HL, Casasnovas J, Rodríguez-Medina JR, et al. Redundant or separate entities?--roles of Twist1 and Twist2 as molecular switches during gene transcription[J]. Nucleic Acids Res, 2011, 39(4): 1177-1186. doi: 10.1093/nar/gkq890
[5] Zhao ZX, Rahman MA, Chen ZG, et al. Multiple biological functions of Twist1 in various cancers[J]. Oncotarget, 2017, 8(12): 20380-20393. doi: 10.18632/oncotarget.14608
[6] Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples[J]. Eur Urol, 2010, 58(1): 96-104. doi: 10.1016/j.eururo.2009.07.041
[7] Teoh JY, Kamat AM, Black PC, et al. Recurrence mechanisms of non-muscle-invasive bladder cancer-a clinical perspective[J]. Nat Rev Urol, 2022, 19(5): 280-294. doi: 10.1038/s41585-022-00578-1
[8] Schöne M, Uhthoff H, Schöne S. Cystoscopy in the outpatient clinical routine: things to keep in mind[J]. Aktuelle Urol, 2023, 54(2): 129-134. doi: 10.1055/a-1867-0560
[9] 张振声, 许传亮, 孙颖浩, 等. 电子膀胱软镜在男性患者门诊手术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2008, 2(2): 114-117.
[10] VandenBussche CJ, Rosenthal DL, Olson MT. Adequacy in voided urine cytology specimens: The role of volume and a repeat void upon predictive values for high-grade urothelial carcinoma[J]. Cancer Cytopathol, 2016, 124(3): 174-180. doi: 10.1002/cncy.21634
[11] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)尿路上皮癌诊疗指南-2023[M]. 北京: 人民卫生出版社, 2023.
[12] Zhu QQ, Ma C, Wang Q, et al. The role of TWIST1 in epithelial-mesenchymal transition and cancers[J]. Tumour Biol, 2016, 37(1): 185-197. doi: 10.1007/s13277-015-4450-7
[13] Cai H, Ke ZB, Chen JY, et al. Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1[J]. Oncogene, 2024, 43(10): 703-713. doi: 10.1038/s41388-023-02936-8
[14] Kim YJ, Kim WJ. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?[J]. Investig Clin Urol, 2016, 57(Suppl 1): S77-S88. doi: 10.4111/icu.2016.57.S1.S77
[15] Reinert T, Borre M, Christiansen A, et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation[J]. PLoS One, 2012, 7(10): e46297. doi: 10.1371/journal.pone.0046297
[16] Yegin Z, Gunes S, Buyukalpelli R. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients[J]. DNA Cell Biol, 2013, 32(7): 386-392. doi: 10.1089/dna.2013.2030
[17] 陆明, 钱麟, 潘彬, 等. 荧光定量PCR检测膀胱癌患者尿沉淀细胞TWIST1基因启动子甲基化状态的临床价值[J]. 南京医科大学学报(自然科学版), 2012, 32(3): 395-398. https://www.cnki.com.cn/Article/CJFDTOTAL-NJYK201203023.htm
[18] Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis[J]. Ann Intern Med, 2015, 163(12): 922-931. doi: 10.7326/M15-0997
[19] Silva-Ferreira M, Carvalho JA, Salta S, et al. Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: a systematic review and meta-analysis[J]. Eur Urol Focus, 2024: S2405-S4569(24)00088-9.
[20] Zhang CC, Xu XH, Wang T, et al. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder[J]. Sci Rep, 2024, 14(1): 7941. doi: 10.1038/s41598-024-58586-7
-